Smart Equity Invest

← Results dashboard

Q2 FY27 · NSE: DIVISLAB

Divi's Laboratories

Results filed 7 November 2026 · Market cap ₹3,03,749 crore · PE 88.9

GrowthGuidance maintainedTranscript read

Revenue
+35.4%
on a year ago
EBITDA
+76.4%
on a year ago
Profit to shareholders
+63.6%
on a year ago
EBITDA margin
42.6%
+1.9 pts on last quarter

Divi's Laboratories reported strong Q2 FY27 performance with total consolidated income rising 32% YoY to ₹3,770 crores and net profit expanding 64% YoY to ₹1,127 crores. The performance was supported by a rich Custom Synthesis mix (62% of H1 sales) and backward integration benefits that reduced net material consumption to 32% of sales. However, working capital absorption—notably an inventory build-up to ₹5,325 crores—led to a 50% decline in pre-tax operating cash flow during H1.

Divi's Laboratories Limited, Q2 FY27₹ crore, consolidated
Q2 FY27Q1 FY27vs previous quarterQ2 FY26vs a year ago
Revenue3,6763,080+19.4%2,715+35.4%
Operating profit (EBIT)1,4241,122+26.9%775+83.7%
Operating margin38.7%36.4%+231 bps28.5%+1019 bps
Other income9464+46.9%145−35.2%
Exceptional items00–0–
Profit before exceptional items and tax1,5051,180+27.5%912+65.0%
Profit to shareholders1,127902+24.9%689+63.6%
Earnings per share (₹)42.4933.95+25.2%25.97+63.6%

Source: Divi's Laboratories Limited’s filing to NSE, 7 November 2026. Operating profit is revenue less every expense except interest, so it leaves out other income and exceptional items. n.m.: not meaningful, because the earlier figure was zero or negative, or the latest one is a loss.

What stood out

  • Significant gross margin expansion driven by product mix and backward integration
    SourceNet material consumption for the first half fell to approximately 32% of sales revenue from 40% in the prior year period, driven by a higher Custom Synthesis mix (62%) and backward integration at the Unit 3 Kakinada facility (Nilima Prasad Divi, Transcript, original pages 6, 9).
  • Substantial capex execution with rising capitalization and multi-year investment plans
    SourceThe company capitalized assets of ₹772 crores in Q2 (total H1 capitalization ₹1,223 crores), with CWIP at ₹1,638 crores as of September 30, 2026, and guided to an annual capex run rate of ~₹2,000 crores (+/- 20%) over the next 2-3 years (Nilima Prasad Divi, Transcript, original pages 6, 11, 15).
  • Sharp divergence between reported profit growth and operating cash flows
    SourceWhile PBT grew 63.2% in H1 to ₹2,685 crores, cash flow from operations before tax declined ~50% to ₹959 crores due to major working capital absorption, including inventory rising to ₹5,325 crores (Shyam Srinivasan & Nilima Prasad Divi, Transcript, original pages 6, 7, 11-12, 18).

Guidance

MetricGuidancePeriod
Revenue Growth
SourceNilima Prasad Divi: 'As we historically said, we would look at a double-digit growth... double-digit growth is the way forward' (Transcript, original page 11).
Double-digit growthH2 FY27 and medium term
Annual Capital Expenditure
SourceNilima Prasad Divi: 'the next two, three years, I would say, if I'm looking at it, ₹2,000 crores plus or minus 20% is something I would do look at year on year' (Transcript, original page 11, 14, 15).
~₹2,000 crores (+/- 20%) per yearNext 2 to 3 years

Reiterated long-term stance of double-digit revenue growth and ~₹2,000 crore annual capex spend.

Tailwinds

  • Strong revenue share from high-margin Custom Synthesis (CDMO) segment
    SourceCustom synthesis accounted for 62% of sales revenue during H1 FY27, supporting consolidated sales growth of 32% YoY in Q2 (Nilima Prasad Divi, Transcript, original pages 6, 7).
  • Significant reduction in raw material consumption intensity
    SourceNet material consumption dropped from 40% of sales in H1 FY26 to 32% in H1 FY27, helped by higher CS contribution and backward integration at Kakinada (Nilima Prasad Divi, Transcript, original pages 6, 9).
  • Healthy volume momentum across generic API business
    SourceGeneric business performance was 'supported by healthy volume growth across the business segment' offsetting pricing pressures (Dr. Kiran S. Divi, Transcript, original page 3).

Headwinds

  • Elevated petrochemical-based solvent costs and input price inflation
    Source'we have witnessed increased volatility in input costs, particularly in petrochemical-based solvents, where prices have remained elevated' (Nilima Prasad Divi, Transcript, original page 5).
  • Global freight disruptions and extended shipping transit times
    SourceSecurity concerns in the Red Sea and Suez Canal led shipping lines to take alternate routes, causing higher ocean freight and longer lead times alongside higher air freight costs (Nilima Prasad Divi, Transcript, original page 5).
  • Sharp decline in net forex gains
    SourceNet forex gain dropped to ₹20 crores in H1 FY27 from ₹103 crores in H1 FY26 (Nilima Prasad Divi, Transcript, original page 6).
  • Persistent pricing pressure in generic product categories
    Source'While pricing pressures persist in certain product categories, we continue to maintain our focus on market competitiveness' (Dr. Kiran S. Divi, Transcript, original page 3).

New businesses and products

capacity expansion · In validation stages; one project is near commercialization, and two others are expected to commercialize over the next one to two quarters

Three dedicated CDMO investment projects

Expected benefit
Dedicated commercial supplies utilizing specialized technologies like flow chemistry and high-throughput processes
Risks
Subject to customer qualification and regulatory agency clearances/inspections; facilities are dedicated and cannot be repurposed for other products
Timeline
Commercialization starting over the next 1-2 quarters
Investment
Part of ongoing capex (CWIP ₹1,638 crores)
SourceDr. Kiran S. Divi: 'Our three major capital investment programs are also progressing through their respective validation stages... one of them is very close to commercialization, other two we expect in the next one or two quarters' (Transcript, original pages 4, 9, 10, 13).

capacity expansion · Ongoing installation and validation

Peptide capacity expansion (SPPS lines)

Expected benefit
Scale to become a top-three global peptide player; handling innovative long-chain peptides from building blocks to large fragments
Risks
Customer qualification timelines, complexity of downstream purification/isolation, strict reliance on innovator demand (no generic peptides currently)
Timeline
Next few years
Investment
Not specifically broken out; included in the ~₹2,000 crore annual capex umbrella
SourceDr. Kiran S. Divi: 'We continue to add capacity and are currently installing several 3,000 litre SPPS lines... with the futuristic capacity, we will be in the top three players' (Transcript, original pages 4, 12).

capacity expansion · Operational and scaling up

Unit 3 Kakinada backward integration and pre-chemistry manufacturing

Expected benefit
Securing key raw materials, lowering material consumption costs, and freeing up manufacturing space in Units 1 and 2
Timeline
Phased implementation ongoing
Investment
Not quantified separately
SourceDr. Kiran S. Divi & Nilima Prasad Divi: 'The facility is supporting our backward integration strategy through selected pre-chemistry operations while enabling the phased transfer of manufacturing activities from the existing facilities' (Transcript, original pages 4, 9, 15).

Things to check

  • Severe cash flow conversion deterioration caused by high inventory lock-up
    SourceCash flow from operations before tax dropped by ~50% to ₹959 crores in H1 FY27 despite a 63% increase in PBT, with inventories rising to ₹5,325 crores (including a ₹1,197 crore increase in FG and WIP) (Shyam Srinivasan & Arindam Mukherjee, Transcript, original pages 7, 11-12, 18).

How the call went

Management was extremely guarded, invoking non-disclosure agreements and confidentiality on nearly every product-level, customer-level, and segment-specific question. They gave little granular color on working capital drag, peptide capacity, or the margin impact of validation batches.

Specific or vague
Low to medium. Management reported high-level figures for revenue splits and total capex/CWIP, but repeatedly refused to provide specific figures on validation batch revenue, capacity numbers, or project splits.
Candour
Low. Citing NDAs and customer confidentiality, management deflected questions on specific molecule traction, GLP-1/peptide split, and commercial batch economics.
The hard questions
Analysts probed deeply into the divergence between cash flow from operations and net profit, potential genericization of key CDMO molecules (sacubitril/valsartan), and the sustainability of gross margins once validation batches transition to commercial. Management gave generic qualitative responses or cited confidentiality.

What analysts pressed on

  • Whether the 40%+ EBITDA margins and ~50% CS growth are temporarily inflated by one-off validation batches.
  • Cash flow from operations falling 50% despite strong PBT growth due to working capital lock-up in inventories.
  • Upcoming loss of exclusivity (LOE) risks on key CDMO customer molecules like sacubitril/valsartan.
  • Capacity limits, downstream peptide purification bottlenecks, and asset turnover for new peptide assets.

Answers that sidestepped

  • Refusal to break down or quantify the revenue or margin contribution of validation batches versus base CDMO business (Dr. Kiran S. Divi, Transcript, original page 7).
  • Deflection of questions regarding genericization impact on sacubitril/valsartan citing CDMO confidentiality (Nilima Prasad Divi, Transcript, original page 11).
  • Deflection on whether EBITDA margin guidance is being upgraded following two quarters of 40%+ EBITDA margins (Nilima Prasad Divi, Transcript, original page 17).
  • Refusal to disclose total installed or planned SPPS peptide capacity numbers citing NDAs (Dr. Kiran S. Divi, Transcript, original page 12).

Numbers against the story

Management emphasized strong ongoing demand, high validation activity, and structural margin improvements from backward integration. However, reported numbers reveal a substantial cash flow divergence, with operating cash flow falling by half due to massive inventory absorption (FG/WIP and 3-month raw material buffer), leaving open the risk that near-term revenue and gross margins (~68%) were aided by high-margin validation batches ahead of commercial ramp-up.

Sources

  • Concall transcript · filed 13-Nov-2026
  • Figures: the company’s results filing with NSE, linked under the table.

Notes written by gemini-3.8-flash from the documents above on 15 November 2026. They summarise what the company said and can contain mistakes: check the source passage before relying on a point. Not investment advice.